Back to top
more

KALA BIO, Inc. (KALA)

(Delayed Data from NSDQ)

$6.85 USD

6.85
2,750

-0.05 (-0.73%)

Updated May 13, 2024 11:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

by Zacks Equity Research

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

by Zacks Equity Research

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Kala Pharmaceuticals (KALA) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA

by Zacks Equity Research

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals

by Zacks Equity Research

CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.

4 Biotech Stocks to Consider for Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

Axsome (AXSM) Stock Up 17% in Six Months: Here's Why

by Zacks Equity Research

Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.

Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate

by Zacks Equity Research

Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

by Zacks Equity Research

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

by Zacks Equity Research

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

by Zacks Equity Research

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

by Zacks Equity Research

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

Kala Pharmaceuticals (KALA) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

How Much Upside is Left in Kala Pharma (KALA)? Wall Street Analysts Think 143.91%

by Zacks Equity Research

The consensus price target hints at a 143.9% upside potential for Kala Pharma (KALA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

by Zacks Equity Research

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

Wall Street Analysts Think Kala Pharma (KALA) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Kala Pharma (KALA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up

by Zacks Equity Research

Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.

Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session.

Gilead (GILD) Reports Positive Data From Urothelial Cancer Study

by Zacks Equity Research

Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.